pr3

Photoregulin3 is a inhibitor of rod photoreceptor gene expression, potentially though Nr2e3 modulation.

GPR34 receptor antagonist 2 (Tyrosine, N-[(2E)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-1-oxo-2-propen-1-yl]-O-(phenylmethyl)-) is an anti-inflammatory agent.

GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM, respectively.

GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50 value of 1.4 μg in the β-arrestin recruitment assay.GPR35 agonist 3 is used in the study of cancer, type 2 diabetes, and cardiovascular disease.

SPR39, a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrates inhibitory Ki values of 0.252 µM for SARS-CoV-2 Mpro, and 3.38 and 7.88 µM for human Cathepsin L (hCatL) and human Cathepsin B (hCatB) respectively. It exhibits antiviral properties and cytotoxicity.

GPR35 agonist 1 is a highly effective and specific GPR35 CXCR8 agonist (EC50: 5.8 nM).

Gpr35modulator 3 (Example 105) is a Gpr35 regulator with an IC50 of less than 1 μM. It is utilized in research related to proliferation, immune response, and inflammation.

Gpr35modulator 2 (compound 52) serves as a modulator for GPR35. It is utilized in researching a variety of diseases related to GPR35.

Gpr35modulator 1 (compound 1-18) acts as an effective modulator of Gpr35, demonstrating an IC50 of less than or equal to 100 nM in HEK293 cells stably transfected with human GPR35.

GPR35activator-1 (example 5) is an effective activator of GPR35, exhibiting a Ki of 0.08 nM for human GPR35.

CPR3 is a PROTAC that targets both IGF-1R and Src.

GPR30 agonist-1 is a compound that acts as an agonist for G protein-coupled receptor 30 (GPR30), inducing vasorelaxation.

SPR38, a potent inhibitor of the SARS-CoV-2 main protease, exhibits a Ki value of 0.260 μM. Additionally, it effectively inhibits human cathepsin L (hCatL) and human cathepsin B (hCatB), displaying Ki values of 1.92 μM and 11.1 μM, respectively.

Compound 5e, a GPR34 receptor antagonist, exhibits selective inhibition of lysophosphatidylserine-induced ERK1 2 phosphorylation in a dose-dependent manner, demonstrating an IC50 value of 0.680 μM without significant cytotoxicity. Additionally, it displays antisensory activity in a mouse neuropathic pain model [1].

GPR3 agonist-2 (compound 32) is a potent full agonist of the G protein-coupled receptor 3 (GPR3), exhibiting an IC50 value of 260 nM [1].

BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor, is effective orally and can inhibit various SARS-CoV-2 variants. It exhibits EC 50 values of 0.62 µM for SARS-CoV-2 and 0.14 µM for HCoV-229E, demonstrating potent anti-pancoronavirus activity at submicromolar concentrations. Additionally, BPR3P0128 displays synergistic antiviral effects when used in combination with Remdesivir [1].

Compound 6 (3,5-dinitro-bisphenol A), also known as GPR35 agonist 5, exhibits weak GPR35 agonistic activity. This compound causes G1 Go phase arrest in CHO-S cells [1].